Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 164 Breast Neoplasms 111 Colorectal Neoplasms 77 Neoplasms 64 Lung Neoplasms 61 Pancreatic Neoplasms 56 Stomach Neoplasms 52 Neoplasm Metastasis 51 Ovarian Neoplasms 45 Rectal Neoplasms 43 Esophageal Squamous Cell Carcinoma 38 Esophageal Neoplasms 38 Head and Neck Neoplasms 34 Squamous Cell Carcinoma of Head and Neck 32 Leukemia, Myeloid, Acute 32 Triple Negative Breast Neoplasms 25 Recurrence 25 Small Cell Lung Carcinoma 24 Precursor Cell Lymphoblastic Leukemia-Lymphoma 24 Colonic Neoplasms 23 Nasopharyngeal Carcinoma 22 Glioblastoma 22 Uterine Cervical Neoplasms 21 Lymphoma 21 Lymphoma, Non-Hodgkin 20 Fallopian Tube Neoplasms 20 Prostatic Neoplasms 17 Melanoma 17 Sarcoma 16 Leukemia 16

Interventions

Etoposide 3 Carboplatin 3 Paclitaxel 2 sintilimab 1 pembrolizumab 1 olaparib 1 ceralasertib 1 atezolizumab 1 apatinib 1 anlotinib 1 Topotecan 1 Platinum 1 Immune Checkpoint Inhibitors 1 Drug Therapy 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

SCLC × Drug Therapy × Clear all

NCT07145333 2025-09-08

Drug-SNP

Medicine Invention Design, Inc

Phase 2/3 Active not recruiting

SCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡